Drug Hunter published recent Ph. 2b ACCESS data showing that Structure Therapeutics' aleniglipron entered a clinically meaningful weight loss phase with no apparent plateau at week 36 and continued weight reductions in the open-label extension.

Drug Hunter™ is reinventing drug discovery intelligence for R&D-focused organizations turning molecules into medicines. Every day, drug discovery strategies, tactics, challenges and solutions are disclosed, but the knowledge is fragmented across journals, conferences, patents, databases, news, company reports, filings and endless other sources, making it challenging to find and apply. Drug Hunter’s experts keep you current by connecting the dots, distilling industry lessons from thousands of sources into a one-of-a-kind searchable platform for drug discovery knowledge you can apply to make better decisions and solve critical discovery challenges. Founded and run by a team of industry scientists, Drug Hunter now serves >200 innovative institutions worldwide including top pharma and biotech companies, investors, and non-profits.

Founded 2018